BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240213
DTEND;VALUE=DATE:20240216
DTSTAMP:20260516T004424
CREATED:20231101T110512Z
LAST-MODIFIED:20231101T111904Z
UID:38062-1707782400-1708041599@www.pharmajournalist.com
SUMMARY:4th Gene Therapy Comparability Summit
DESCRIPTION:As we witness a surge in later-stage clinical trials within the gene therapy industry\, the spotlight on comparability has never been brighter. That’s why we’re thrilled to announce the return of the 4th Gene Therapy Comparability Summit\, taking place in Boston\, MA\, February 13-15. \n \nThis event is your gateway to uncovering how to implement effective comparability studies to overcome strategic and technical hurdles to expedite more gene therapy approvals. \nWhat to expect at the 2024 meeting: \n\nGain valuable insights from CSL Behring\, Bayer\, Ultragenyx\, and other industry leaders on the transition to in-house manufacturing\, effective variability management\, and ensuring consistency across multiple facilities.\nExamine Sarepta’s considerations before and after receiving regulatory approval and investigate the distinctions among global regulatory agencies with insights from Novartis\, Sarepta\, and Adverum.\nStrengthen your analytical toolbox and enhance comparability studies through case studies and strategies to reduce variability with AskBio and BioMarin.\nStay ahead of the latest advancements in process development for improved characterization and analysis of AAV-gene therapies\, with a focus on minimizing process alterations\, featuring contributions from Abbvie and Spark Therapeutics.\nHarness strategic insights from cell therapy study design\, innovative analytical techniques\, and regulatory expertise to enhance your gene therapy comparability protocols\, supported by Novartis.\n\nDon’t miss this unparalleled opportunity to stay at the forefront of gene therapy comparability. Join us and gain the knowledge\, tools\, and connections to secure your gene therapy approval. \nDownload the full event guide here to view the full expert speaker line up and see who else you will meet: https://ter.li/rrefvp
URL:http://www.pharmajournalist.com/event/4th-gene-therapy-comparability-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240213
DTEND;VALUE=DATE:20240216
DTSTAMP:20260516T004424
CREATED:20231123T125801Z
LAST-MODIFIED:20240117T112321Z
UID:38209-1707782400-1708041599@www.pharmajournalist.com
SUMMARY:3rd mRNA Analytical Development Summit
DESCRIPTION:100+ Technical mRNA Specialists | 35+ Expert Speakers \nAs access to faster and higher-throughput analytical methods becomes increasingly vital\, it is critical that we employ superior analytical approaches for mRNA-based therapeutics and vaccines to ensure high quality and effective drugs are approved\, whilst adhering to regulatory guidelines. \nThe 3rd mRNA Analytical Development Summit returns to Boston in February to seek and discuss new guidelines and identify a path forward with tangible best practices to ensure reliable analytical methods are guiding mRNA production\, purification and formulation optimization for approval of high quality\, compliant mRNA drugs for patients in need. \nDownload the three day program here: https://ter.li/pi54tj \n100+ Heads\, Directors and Senior Scientists of Analytical Development\, Quality Control\, CMC and Regulatory Affairs will deep dive into analytical development techniques and challenges within mRNA drug product and drug substance\, eager to glean insights into future analytical methods to safeguard regulatory submissions in 2024 and beyond. \nJoin them and register your place here: https://ter.li/d6nqe3
URL:http://www.pharmajournalist.com/event/3rd-mrna-analytical-development-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR